ccredo) and CVS Caremark (Caremark) to distribute both Remodulin and Tyvaso. The company sells Adcirca to pharmaceutical wholesalers. The company sells subcutaneous and intravenous Remodulin outside the United States to various distributors, each of which has exclusive distribution rights in one or more countries within Europe, Israel and the Middle East, Asia and South and Central America. The company also distributes Remodulin in Canada through a specialty pharmaceutical wholesaler. Intellectual Property The company conducts research into new methods to synthesize treprostinil and has filed additional patent applications relating to production of treprostinil, several of which have already been granted in the United States. In addition to the treprostinil patents, the company has additional patents specific to its individual treprostinil-based products, including the following: Remodulin: The company has been granted three U.S. patents covering an improved diluent for Remodulin, which would expire in 2028 and 2029. Tyvaso: The company has been granted two U.S. patents, as well as patents in other countries for Tyvaso that cover methods of treating PAH by inhaled delivery. These patents would expire in the United States in 2018. Orenitram: The company’s patents for Orenitram cover methods of use for treating PAH, orally administered formulations, controlled moisture storage and production methods, as well as those covering controlled release formulations licensed to the company by Supernus Pharmaceuticals Inc. (Supernus). These patents would expire in the United States between 2024 and 2031 and in various countries throughout the world between 2024 and 2027. The company has additional pending U.S. and international patent applications relating to Remodulin, Tyvaso and Orenitram. Research and Development The company’s research and development expenses, as of December 31, 2013, totaled approximately $299.3 million. Suppliers Accredo Health Group, Inc. and CVS Caremark distributes and sells Remodulin and Tyvaso in the United States. Eli Lilly and Company manufactures and supplies Adcirca for the company. History United Therapeutics Corporation was founded in 1996. The company was incorporated in Delaware in 1996.
united therapeutics corp (UTH:Frankfurt)
1040 Spring Street
Silver Spring, MD 20910
|Actelion Ltd||SFr.102.00 CHF||+1.20|
|Alexion Pharmaceuticals Inc||$183.24 USD||-4.81|
|Celanese Corp||$53.76 USD||-0.08|
|Nippon Shinyaku Co Ltd||¥3,905 JPY||+100.00|
|Vertex Pharmaceuticals Inc||$110.14 USD||-4.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.